The study recommended biologic therapies, including anti-IgE, anti-IL-4/13, and anti-IL-5 agents, for children with definite phenotypes of chronic asthma, indicating substantial improvements in asthma symptom control and management. This evidence concerns the gene IL5 and chronic asthma.